Discordance in HIV‐1 Co‐receptor use prediction by different genotypic algorithms and phenotype assay: Intermediate profile in relation to concordant predictions

Concordant and discordant genotypic predictions of HIV‐1 co‐receptor tropism were analyzed. V3 region was sequenced from plasma samples of patients screened for R5 tropism by the Trofile® assay, before CCR5 antagonist prescription. Ten tools including geno2pheno, PSSM, an “11/25” and “net charge” rule, and other published algorithms were used. Patients were grouped according to concordance or discordance between tools and Trofile® result. Trofile® tropism reports from 50 patient samples were R5 in 38 and Dual/Mixed (DM) in 12. Prediction with the genotypic tools were concordant for 23 R5 samples, and discordant for the 15 other ones. From Trofile® DM strains were concordant in 6 and discordant in 6. V3 sequences were not clearly distinct between R5 and DM strains, except a greater diversity in the later. Discordances were found with any tool or combination of them, so that no one can be proposed as better than the others. Predictive values of each algorithm were similar and rather good (efficacy ranged from 74% to 84%), but the rate of non‐confirmed prediction is greater when compelling the results of all tools with each individual sample. The mean of quantitative values obtained with one tool when another tool give the opposite prediction were different from those obtained when all tools agree with that prediction. The two discordant groups were often not distinguishable from each other. These results suggest that viruses giving discordant prediction with bioinformatic tools could be functionally distinct and/or in a different evolutionary state compared to those with concordant prediction. J. Med. Virol. 84:402–413, 2012. © 2011 Wiley Periodicals, Inc.

[1]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[2]  A. Wensing,et al.  European guidelines on the clinical management of HIV-1 tropism testing. , 2011, The Lancet. Infectious diseases.

[3]  V. Calvez,et al.  Concordance between Two Phenotypic Assays and Ultradeep Pyrosequencing for Determining HIV-1 Tropism , 2011, Antimicrobial Agents and Chemotherapy.

[4]  Jeroen Aerssens,et al.  HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitro. , 2011, Antiviral research.

[5]  Alexander Thielen,et al.  Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. , 2011, The Journal of infectious diseases.

[6]  L. Stuyver,et al.  Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment , 2010, The Journal of antimicrobial chemotherapy.

[7]  F. Gutiérrez,et al.  Performance of Genotypic Algorithms for Predicting HIV-1 Tropism Measured against the Enhanced-Sensitivity Trofile Coreceptor Tropism Assay , 2010, Journal of Clinical Microbiology.

[8]  C. Petropoulos,et al.  Dual-tropic HIV type 1 isolates vary dramatically in their utilization of CCR5 and CXCR4 coreceptors , 2010, AIDS.

[9]  J. Izopet,et al.  High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists , 2010 .

[10]  Andrew J. Low,et al.  Improved Detection of CXCR4-Using HIV by V3 Genotyping: Application of Population-Based and “Deep” Sequencing to Plasma RNA and Proviral DNA , 2010, Journal of acquired immune deficiency syndromes.

[11]  F. Baldanti,et al.  Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group. , 2010, The new microbiologica.

[12]  M. Prosperi,et al.  Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping , 2010, Retrovirology.

[13]  P. Gorry,et al.  Constrained use of CCR5 on CD4+ lymphocytes by R5X4 HIV-1: efficiency of Env-CCR5 interactions and low CCR5 expression determine a range of restricted CCR5-mediated entry. , 2010, Virology.

[14]  C. Charpentier,et al.  Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study , 2010, Antimicrobial Agents and Chemotherapy.

[15]  E. Fenyö,et al.  Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection. , 2010, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

[16]  L. Stuyver,et al.  HIV-1 V3 envelope deep sequencing for clinical plasma specimens failing in phenotypic tropism assays , 2010, AIDS research and therapy.

[17]  E. Poveda,et al.  High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists—authors’ response , 2010 .

[18]  Thomas Lengauer,et al.  V3 Loop Sequence Space Analysis Suggests Different Evolutionary Patterns of CCR5- and CXCR4-Tropic HIV , 2009, PloS one.

[19]  H. Schuitemaker,et al.  Comparison of Human Immunodeficiency Virus Type 1 Tropism Profiles in Clinical Samples by the Trofile and MT-2 Assays , 2009, Antimicrobial Agents and Chemotherapy.

[20]  M. Sagar,et al.  Human Immunodeficiency Virus Type 1 V1-to-V5 Envelope Variants from the Chronic Phase of Infection Use CCR5 and Fuse More Efficiently than Those from Early after Infection , 2009, Journal of Virology.

[21]  M. Hughes,et al.  Assessing Human Immunodeficiency Virus Type 1 Tropism: Comparison of Assays Using Replication-Competent Virus versus Plasma-Derived Pseudotyped Virions , 2009, Journal of Clinical Microbiology.

[22]  P. Massip,et al.  Genotypic Prediction of Human Immunodeficiency Virus Type 1 CRF02-AG Tropism , 2009, Journal of Clinical Microbiology.

[23]  Natalia Chueca,et al.  Improvement in the determination of HIV‐1 tropism using the V3 gene sequence and a combination of bioinformatic tools , 2009, Journal of medical virology.

[24]  E. Poveda,et al.  Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. , 2009, The Journal of antimicrobial chemotherapy.

[25]  J. Mullins,et al.  Evolution of CCR5 Use before and during Coreceptor Switching , 2008, Journal of Virology.

[26]  M. Churchill,et al.  Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. , 2008, Virology.

[27]  L. Cuzin,et al.  Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism , 2008, AIDS.

[28]  E. Poveda,et al.  Performance of a Population-Based HIV-1 Tropism Phenotypic Assay and Correlation With V3 Genotypic Prediction Tools in Recent HIV-1 Seroconverters , 2008, Journal of Acquired Immune Deficiency Syndromes.

[29]  L. Stuyver,et al.  Minor Variant Detection at Different Template Concentrations in HIV-1 Phenotypic and Genotypic Tropism Testing , 2008, The open virology journal.

[30]  Andrew J. Low,et al.  CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals. , 2008, AIDS research and human retroviruses.

[31]  Natalia Chueca,et al.  Evaluation of Eight Different Bioinformatics Tools To Predict Viral Tropism in Different Human Immunodeficiency Virus Type 1 Subtypes , 2008, Journal of Clinical Microbiology.

[32]  V. Calvez,et al.  Comparison of two genotypic algorithms to determine HIV‐1 tropism * , 2008, HIV medicine.

[33]  L. Scudeller,et al.  HIV-1 biological phenotype and predicted coreceptor usage based on V3 loop sequence in paired PBMC and plasma samples. , 2007, Virus research.

[34]  Andrew J. Low,et al.  Predicting HIV Coreceptor Usage on the Basis of Genetic and Clinical Covariates , 2007, Antiviral therapy.

[35]  Tobias Sing,et al.  Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates , 2007, AIDS.

[36]  E. Poveda,et al.  Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use , 2007, AIDS.

[37]  Wei Huang,et al.  Coreceptor Tropism in Human Immunodeficiency Virus Type 1 Subtype D: High Prevalence of CXCR4 Tropism and Heterogeneous Composition of Viral Populations , 2007, Journal of Virology.

[38]  J. Reeves,et al.  Conserved Changes in Envelope Function during Human Immunodeficiency Virus Type 1 Coreceptor Switching , 2007, Journal of Virology.

[39]  Kevin C. Olivieri,et al.  The envelope gene is a cytopathic determinant of CCR5 tropic HIV-1. , 2007, Virology.

[40]  Tobias Sing,et al.  Determining Human Immunodeficiency Virus Coreceptor Use in a Clinical Setting: Degree of Correlation between Two Phenotypic Assays and a Bioinformatic Model , 2006, Journal of Clinical Microbiology.

[41]  Christos J. Petropoulos,et al.  Development and Characterization of a Novel Single-Cycle Recombinant-Virus Assay To Determine Human Immunodeficiency Virus Type 1 Coreceptor Tropism , 2006, Antimicrobial Agents and Chemotherapy.

[42]  B. Clotet,et al.  Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses. , 2006, The Journal of general virology.

[43]  Helen Piontkivska,et al.  HIV type 1 tropism and inhibitors of viral entry: clinical implications. , 2006, AIDS reviews.

[44]  B. Gazzard,et al.  Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. , 2005, The Journal of infectious diseases.

[45]  John P. Moore,et al.  The CCR5 and CXCR4 coreceptors--central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. , 2004, AIDS research and human retroviruses.

[46]  J. Margolick,et al.  Improved Coreceptor Usage Prediction and GenotypicMonitoring of R5-to-X4 Transition by Motif Analysis of HumanImmunodeficiency Virus Type 1 env V3 LoopSequences , 2003, Journal of Virology.

[47]  Jacques Corbeil,et al.  A new perspective on V3 phenotype prediction. , 2003, AIDS research and human retroviruses.

[48]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.